Replies to post #175817 on Anavex Life Sciences Corp (AVXL)

[OFP]

Seem like Sigma-1 receptor agonism may have been an unintended side action of Donepezil, which although not fully understood is thought to have its (limited) effect based on being a centrally acting reversible acetylcholinesterase inhibitor.

There is however research that shows that what little effect Donepezil has may actually instead be related to its Sigma-1 agonism.

Agree it's difficult to tease out via which MOA dzp exerts its "limited" effect. Certainly crafted/intended initially as an ACH-I but back then there was little known of S1R pharmacology and I don't even know if they had identified the S1R agonism at that point. Goes back to the issue of the MOA is not critical to the equation in a retrospective sense if the "A" i.e. action is there.

Perhaps our Anavex-now Mono style advocates have a point. I think what you are saying here is that 2-73 may do S1R agonism better.

Anything is possible but if you are going to invest I'd think you'd want some data to point to that.